ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GT737

A development code. Also written as “GT737 Injection”.

Its studies are mostly in Leukemia, Myeloid, Acute, led by Grit Biotechnology.

Furthest: early phase 1, since Jun 22, 20261 company-led study, 1 open or runningNext primary completion: Jun 2030 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grit Biotechnology11 open or runningearly phase 1since Jun 22, 2026Jun 22, 2026Jun 2030early phase 1 · NCT07676006

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 22, 2026First study: early phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT07676006 · 36 planned · China

Ahead

  1. Jun 2030Primary completion: early phase 1 study in Leukemia, Myeloid, AcuteNCT07676006

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07676006Leukemia, Myeloid, Acute · ChinaEarly 1Not yet recruitingJun 203036

How it is read

Names in the registry

  • “GT737 Injection”, 1 entry

Codes read as this program: GT737.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.